A Phase 4 interventional study of metronidazole 1% gel and azelaic acid 15% gel in Skin Manifestations, sponsored by Galderma R&D. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-01.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Skin Manifestations with a site in United States — 2 open to participants now, 3 under way, 2 of them phase 3. Skin Manifestations · United States.
Among the 10 studies in Skin Manifestations with a site in United States, this one is one of 4 that started in 2010, is one of 2 in phase 4, and was the 4th registered.
29 studies on the registry are indexed under Skin Manifestations; 5 are open to participants now.
Browse Skin Manifestations studies →2 of the 10 studies in Skin Manifestations with a site in United States are open now. Recruiting first, the newest first:
Takeda · Sites in United States, Australia, Bulgaria and 12 more countries
Ages 18+
Takeda · Sites in United States, Australia, Bulgaria and 15 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Skin Manifestations studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 77 is close to the median of 75 across 23 interventional studies indexed under Skin Manifestations.
Median enrollment 77 across the 9 interventional studies, 120 across the 1 observational. Of the 5 that completed or were terminated, 4 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 5 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
Galderma Group AG has 5 studies filed under Skin Manifestations — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Skin Manifestations with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the tolerability of MetroGel® 1% to Finacea® 15% in subjects with healthy skin applied according to product labeling for three weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: metronidazole 1% gel
Drug: azelaic acid 15% gel
Apply topically once daily on one side of the face for three weeks
Also known as: MetroGel® 1% gel
Apply topically twice daily on the opposite side of the face for three weeks
Also known as: Finacea® 15% Gel
Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Scores in Each Assessment (Erythema, Scaling, Dryness, Stinging/Burning) From Baseline to Week 3
Number of participants who were a success with regard to worst post-baseline tolerability scores in each of the tolerability assessments at any time point between baseline and week 3. Tolerability assessments (erythema, scaling, dryness, stinging/burning) are evaluated on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with 0 being best and 4 being worst. Success was defined as a tolerability score of 0.
Time frame: baseline to week 3
Number of Participants Who Were a Success With Regard to Worst-baseline Tolerability Assessment Scores in Each Assessment (Erythema, Scaling, Dryness, Stinging/Burning) on Day 22
Number of participants who were a success with regard to worst-baseline tolerability assessment scores for each assessment (erythema, scaling, dryness, stinging/burning) on day 22. Tolerability assessments (erythema, scaling, dryness, stinging/burning) are evaluated on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with 0 being best and 4 being worst. Success was defined as a tolerability score of 0 for each assessment.
Time frame: day 22
6 Question Subject Preference Survey at Week 3
Number of participants per response to each question of the subject preference survey at week 3
Time frame: 3 weeks
Dates of recruitment period: First subject was enrolled on June 7, 2010 and the last subject was enrolled on June 7, 2010.
| Milestone | MetroGel® 1% and Finacea® Gel 15% |
|---|---|
| Started | 77 |
| Completed | 76 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
Number of participants who were a success with regard to worst post-baseline tolerability scores in each of the tolerability assessments at any time point between baseline and week 3. Tolerability assessments (erythema, scaling, dryness, stinging/burning) are evaluated on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with 0 being best and 4 being worst. Success was defined as a tolerability score of 0.
| participants | MetroGel® 1% | Finacea Gel® 15% |
|---|---|---|
| Erythema | 12 | 13 |
| Scaling | 61 | 60 |
| Dryness | 48 | 48 |
| Stinging/Burning | 65 | 34 |
Number of participants who were a success with regard to worst-baseline tolerability assessment scores for each assessment (erythema, scaling, dryness, stinging/burning) on day 22. Tolerability assessments (erythema, scaling, dryness, stinging/burning) are evaluated on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with 0 being best and 4 being worst. Success was defined as a tolerability score of 0 for each assessment.
| participants | MetroGel® 1% | Finacea Gel® 15% |
|---|---|---|
| Erythema | 33 | 33 |
| Scaling | 69 | 71 |
| Dryness | 50 | 51 |
| Stinging/Burning | 77 | 63 |
Number of participants per response to each question of the subject preference survey at week 3
| participants | MetroGel® 1% and Finacea Gel® 15% |
|---|---|
| 1. Side of face felt better MetroGel® | 21 |
| 1. Side of face felt better Finacea® | 14 |
| 1. Side of face both felt same | 30 |
| 1. Side of face neither felt better | 12 |
| 1. Side of face felt better Missing | 0 |
| 2. Overall impression of MetroGel® Very pleasant | 3 |
| 2. Overall impression of MetroGel® Pleasant | 36 |
| 2. Overall impression of MetroGel® Okay | 34 |
| 2. Overall impression of MetroGel® Unpleasant | 4 |
| 2. Overall impression of MetroGel® Very unpleasant | 0 |
| 2. Overall impression of MetroGel® Missing | 0 |
| 3. Overall impression of Finacea® Very pleasant | 5 |
| 3. Overall impression of Finacea® Pleasant | 26 |
| 3. Overall impression of Finacea® Okay | 38 |
| 3. Overall impression of Finacea® Unpleasant | 5 |
| 3. Overall impression of Finacea® Very unpleasant | 3 |
| 3. Overall impression of Finacea® Missing | 0 |
| 4. Side of face more sensitive MetroGel® | 4 |
| 4. Side of face more sensitive Finacea® | 32 |
| 4. Side of face more sensitive both felt same | 12 |
| 4. Side of face more sensitive Neither | 29 |
| 4. Side of face more sensitive Missing | 0 |
| 5. Which side was easier to use MetroGel®? | 13 |
| 5. Which side was easier to use Finacea®? | 13 |
| 5. Which side was easier to use both equal? | 50 |
| 5. Which side was easier to use Neither? | 1 |
| 5. Which side was easier to use Missing | 0 |
| 6. Which product tell a friend about MetroGel®? | 13 |
| 6. Which product tell a friend about Finacea®? | 11 |
| 6. Which product tell a friend about Both? | 32 |
| 6. Which product tell a friend about Neither? | 21 |
| 6. Which product tell a friend about Missing? | 0 |
Collected over 3 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MetroGel® 1% | — | 0/77 (0%) | 0/77 (0%) |
| Finacea® Gel 15% | — | 0/77 (0%) | 6/77 (7.8%) |
| Event | MetroGel® 1% | Finacea® Gel 15% |
|---|---|---|
| application site pruritusGeneral disorders | 0/77 | 6/77 |
| Age, Continuous(years) | MetroGel® 1% and Finacea® Gel 15% |
|---|---|
| Mean | 42.4 ± 15.07 |
| Sex: Female, Male(Participants) | MetroGel® 1% and Finacea® Gel 15% |
|---|---|
| Female | 61 |
| Male | 16 |
The record gives a start of Jun 2010, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Metronidazole · Azelaic acid